CTKB Q3'26 Earnings: revenue estimate is 53.05M USD

What happened

Cytek Biosciences is scheduled to report its Q3'26 results on November 04 after the market closes, at 4:05 PM ET. The revenue estimate is 53.05 million USD and the earnings per share estimate is (0.07) USD.

Confirmed

Global impact / market context

The revenue estimate of 53.05 million USD is above the prior quarter's reported sales, so investors will compare actual revenue against this figure. The expected loss per share signals continued unprofitability, which may pressure the stock if results miss estimates.

Analyst inference

Cytek beat revenue estimates in three of the four prior quarters shown, including a 2.12% beat in the year-ago period. The most recent revenue surprise was positive but small, suggesting estimates have recently been slightly conservative, which may shape investor positioning.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 53.05 million USD estimate, since prior quarters show Cytek sometimes missed estimates, including one negative revenue surprise. Confirmed
2. Compare reported earnings per share with the (0.07) USD estimate to see if cost control improved, because a narrower loss than expected would suggest operating expenses are falling. Proposed
3. Track how much revenue comes from instrument sales versus recurring consumables, since recurring revenue would give Cytek steadier cash available and reduce reliance on lumpy equipment purchases. Analyst inference

Evidence

• Original source link unavailable